Compare Organon & Co. Common Stock (OGN) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Abrdn Physical Platinum Shares ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Abrdn Physical Platinum Shares ETF trades at $14.66 (market cap $2.00B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Abrdn Physical Platinum Shares ETF for 43 Days on average.
| OGN | PPLT | |
|---|---|---|
Market Cap | $3.61B | $2.00B |
Volume | 1,808,049 | 2,555,573 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $13.81 | $25.23 |
52-Week Low | $5.70 | $13.73 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $15.05, down 1.44% with a bearish technical outlook. Moving averages signal strong selling pressure while oscillators remain neutral. Recent news highlights platinum's underperformance in the precious metals rally, with some analysts viewing it as a potential catch-up trade opportunity despite current bearish technicals.
The ETF faces headwinds from platinum's term structure in contango, suggesting adequate supply. Historical seasonality offers some counterpoint to the bearish outlook. Investment opportunity exists if platinum catches up to gold and silver's recent rally, though supply dynamics and technical weakness present near-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
